Expertos Invitados





DIAGNOSTICO Y TRATAMIENTO DEL SINDROME SEROTONINERGICO

(especial para SIIC © Derechos reservados)
El síndrome serotoninérgico es un evento adverso grave frecuente, potencialmente letal, producido como consecuencia del tratamiento farmacológico, por una sobredosis intencional o por una interacción farmacológica inadvertida.
Autor:
Andrew Monte
Columnista Experto de SIIC

Institución:
University of Massachusetts Medical Center

Artículos publicados por Andrew Monte
Coautores
Dana Resop* Alison Hayward** Edward Boyer*** 
MD, University of Massachusetts Medical Center, EE.UU.*
University of Massachusetts Medical Center, EE.UU.**
MD, PhD, University of Massachusetts Medical Center, EE.UU.***
Recepción del artículo
17 de Abril, 2008 		Aprobación
24 de Junio, 2008
Primera edición
3 de Noviembre, 2009 		Segunda edición, ampliada y corregida
7 de Junio, 2021

DIAGNOSTICO Y TRATAMIENTO DEL SINDROME SEROTONINERGICO

Resumen
El síndrome serotoninérgico (SS) es un evento adverso grave frecuente, potencialmente letal, que se produce como consecuencia del tratamiento farmacológico, por una sobredosis intencional o por una interacción farmacológica inadvertida. Para comprender el SS es necesario considerar tres características. Primero, el SS no es una reacción idiopática a las drogas, es una consecuencia anticipada del exceso de participación serotoninérgica del sistema nervioso central (SNC) y de los receptores serotoninérgicos periféricos. Segundo, el SS produce un amplio espectro de condiciones clínicas. Tercero, las manifestaciones clínicas del SS varían desde escasamente perceptibles a letales. Esta revisión detalla los medicamentos que se encuentran asociados al SS, describe los criterios diagnósticos y delinea las estrategias terapéuticas.

Palabras clave
síndrome serotoninérgico, etiología, criterios diagnósticos, serotonin syndrome


Artículo completo
(castellano)
Extensión:  +/-11.14 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

The Serotonin Syndrome

Abstract
The serotonin syndrome (SS) is a common, potentially life threatening adverse drug event that results from therapeutic drug use, intentional overdose, or inadvertent drug-drug interactions. Three features of SS are critical to understanding the disorder. First, SS is not an idiopathic drug reaction; it is a anticipated consequence of excess serotonergic agonism of central nervous system (CNS) and peripheral serotonergic receptors. Second, presentations of SS occur across a spectrum of clinical findings. Third, clinical manifestations of SS vary from barely perceptible to lethal. This review will describe medications associated with SS, describe diagnostic criteria, and outline management strategies.

Key words
etiology, diagnostic criteria


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Salud Mental, Toxicología
Relacionadas: Cuidados Intensivos, Educación Médica, Farmacología, Geriatría, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 11.14 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Edward Boyer, Department of Emergency Medicine University of Massachusetts Medical School, MA 01655, 55 Lake Ave North,, Worcester, EE.UU.
Bibliografía del artículo
1. Sternbach H. The serotonin syndrome. American Journal of Psychiatry 148:705-13, 1991.
2. Dunkley E, Isbister G, Sibbritt D, Dawson A, Whyte I. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Quarterly Journal of Medicine 96:635-42, 2003.
3. Oates J, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 10:1076-8, 1960.
4. Sampson E, Warner J. Serotonin syndrome: Potentially fatal but difficult to recognize. British Journal of General Practice 49:871-72, 1999.
5. Martin T. Serotonin syndrome. Annals of Emergency Medicine 28:520-6, 1996.
6. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. Journal of Emergency Medicine 16:615-19, 1998.
7. Isbister G, Bowe S, Dawson A, Whyte I. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Journal of Toxicology-Clinical Toxicology 42:277-85, 2004.
8. Litovitz T, Klein-Schwartz W, Caravati E. Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 22:517-75, 2003.
9. Mackay F, Dunn N, Mann R. Antidepressants and the serotonin syndrome in general practice. British Journal of General Practice 49:871-4, 1999.
10. Hegerl U, Bottlender R, Gallinat J, Kuss H, Ackenheil M, Moller H. The serotonin syndrome scale: First results on validity. European Archives of Psychiatry and Clinical Neuroscience 248:96-103, 1998.
11. Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Annals of Emergency Medicine 33:457-9, 1999.
12. Isbister G, Dawson A, Whyte I, Prior F, Clancy C, Smith A. Neonatal paroxetine withdrawal syndrome of actually serotonin syndrome. Archives of Disease in Childhood 85:F145-8, 2001.
13. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Archives of General Psychiatry 60:720-6, 2003.
14. Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71(4):837-44, 2002.
15. Lee D, Lee C. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 19:894-6, 1999.
16. Gardner D, Lynd L. Sumatriptan contraindications and the serotonin syndrome. Annals of Pharmacotherapy 32:33-8, 1998.
17. Giese S, Neborsky R. Serotonin syndrome: Potential consequences of Meridia combined with demerol or fentanyl. Plastic and Reconstructive Surgery 107:293-4, 2001.
18. DaSilva K, LeFlore D, Marston B, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 15:1281-85, 2001.
19. Callaway J, Grob C. Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse reactions. Journal of Psychoactive Drugs 30:367-69, 1998.
20. Izzo A, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs 61:2163-75, 2001.
21. Asch D, Parker R. The Libby Zion case: One step forward to two steps backward? New England Journal of Medicine 318:771-5, 1988.
22. Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: Plasma level-correlated symptomatology. Journal of Clinical Psychopharmacology 22:440-41, 2002.
23. Turkel S, Nadala J, Wincor M. Possible serotonin syndrome in association wiht 5-HT3 antagonist agents. Psychosomatics 42:258-60, 2001.
24. Kaneda Y, Kawamura I, Fujii A, Ohmori T. Serotonin syndrome--'potential' role of the CYP2D6 genetic polymorphism in Asians. International Journal of Neuropsychopharmacology 5:105-6, 2002.
25. Mitchell P. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 17:390-406, 1997.
26. Demirkiran M, Jankivic J, Dean J. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clinical Neuropharmacology 19:157-64, 1996.
27. Gillman PK. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust 167(2):109-11, 1997.
28. Wigen C, Goetz M. Serotonin syndrome and linezolide. Clinical Infectious Diseases 34:1651-53, 2002.
29. Narita M, Tsuji B, Yu V. Linezolid-associate peripheral and opitc neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007:1189-97, 2007.
30. DeBellis R, Schaefer O, Liquori M, Volturo G. Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in critically ill bone marrow recipient. J Intensive Care Med 20:351-3, 2005.
31. Sola C, Bostwick J, Hart D, Lineberry T. Anticipating potential linezolide-SSRI interaction in the general hospital setting: a MAOI in disguise. Mayo Clin Proc 81:330-4, 2006.
32. Lawrence K, Adra M, PK G. Serotonin toxcitiy associate with the use of linezolid: a review of postmarketing data. Clin Infect Dis 42:1578-83, 2006.
33. Taylor J, Wilson J, Estes L. Linezolid and serotonergic drug interactions: A retrospective survey. Clin Infect Dis 43:180-7, 2006.
34. Huang J, Gortney J. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 26:1784-93, 2006.
35. Morales-Molina J, Mateu de Antonio J, Marin-Casino M, Grau S. Linezolid-associated serotonin syndrome: What we can learn from cases reported so far. J Antimicrob Chemother 56:1176-8, 2005.
36. Clark D, Andrus M, Byrd D. Drug interaction between linezolid and selective serotonin reuptake inhibitors: Case report involving sertraline and review of the literature. Pharmacotherapy 26:269-76, 2006.
37. Information for healthcare professionals: selective serotoinin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors, (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). Washington, DC, 2006. Accessed at www.fda.gov/cder/drug/infosheets/hcp/triptanshcp.htm.
38. Mahlverg R, Kunz D, Sasse J, Kirchheimer J. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 161:1129, 2004.
39. Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. Clin Neurpharmacol 27:150-1, 2004.
40. Houlihan A. Serotoinin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazipine. Annals of Pharmacotherapy 38:411-3, 2004.
41. Gnanadesigan N, Espinoza R, Smith R, Israel M, Reuben. Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected? Journal of the American Medical Directors Association 6:265-9, 2005.
42. Karunatilke H, Buckley N. Serotonin syndrome induced by fluvoxamine and oxycodone. Annals of Pharmacotherapy 40:155-7, 2006.
43. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics, and serotonin toxicity. Br J Anesth 95:434-41, 2005.
44. Hoyer D, Clarke D, Fozard J, Hartig P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine. Pharmacology Reviews 46:157-203, 1994.
45. VanOekelen D, Megens A, Meert T, Luyten W, Leysen J. Functional study of rat 5-HT2A receptors using antisense oligonucleotides. Journal of Neurochemistry 85:1087-100, 2003.
46. Isbister G. Serotonin syndrome, mydriasis, and cyproheptadine. Annals of Pharmacotherapy 35:1672, 2001.
47. Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Memantine, and NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry 37:57-62, 2004.
48. Isbister G, Whyte I. Serotonin toxicity and malignant hyperthermia: role of 5-HT receptors. British Journal of Anaesthesia 88:603-4, 2002.
49. Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Research 890:23-31, 2001.
50. Done C, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1 and 5-HT2 receptors: Microdialysis studies in teh awake and anaesthetized rat. Neuropharmacology 33:411-21, 1994.
51. Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of teh serotonin syndrome. Neurochemistry International 43:155-64, 2003.
52. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Case report. Pharmacopsychiatry 39:159-61, 1996.
53. Kline S, Mauro L, Scala-Barnet D, Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clinical Pharmacology 8:510-14, 1989.
54. Mason P, Morris V, Balcezak T. Serotonin syndrome: Presentation of 2 cases and review of the literature. Medicine 79:201-9, 2000.
55. Kaneda Y, Ohmori T, Fujii A. The serotonin syndrome: Investigation using the Japanese version of the Serotonin Syndrome Scale. Psychiatry Research 105:135-42, 2001.
56. Buloh R, Dietz J, Spooner J. Myoclonus and ocular oscillations produced by L-tryptophan. Annals of Neurology 11(95-7), 1982.
57. Whyte I, Dawson A. Redefining the serotonin syndrome. Journal of Toxicology-Clinical Toxicology 40:668-9, 2002.
58. Ali S, Taguchi A. Malignant hyperthermia. Best Practice and Research Clinical Anesthesiology 17:519-33, 2003.
59. Guze B, Baxter L. Current Concepts: Neuroleptic malignant syndrome. New England Journal of Medicine 313:163-6, 1985.
60. Gillman P. The serotonin syndrome and its treatment. Journal of Psychopharmacology 13:100-9, 1999.
61. Hick J, Smith S, Lynch M. Metabolic acidosis in restraint-associated cardiac arrest: a case series. Academic Emergency Medicine 6:239-45, 1999.
62. Kapur S, Zipursky R, Jones C, Wilson A, Dasilva J. Cyproheptadine: A potent in vivo serotonin antagonist. American Journal of Psychiatry 154:884, 1997.
63. Boddy R, Ali R, Dowsett R. Use of sublingual olanzepine in serotonin syndrome. Journal of Toxicology-Clinical Toxicology 42:725, 2004.
64. Olsen D, Dart R, Robinett M. Severe serotonin syndrome from escitalopram overdose. Journal of Toxicology-Clinical Toxicology 42:744-5, 2004.
65. Snider S, Hutt C, Stein B, Fahn S. Increase in brain serotonin produced by bromocriptine. Neuroscience Letters 1:237-41, 1975.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008